With Twists And Turns, KaloBios Goes Public
It wasn’t pretty, but KaloBios Pharmaceuticals went public and raised $70 million in late January, the first IPO for a US antibody company in more than a decade.
It wasn’t pretty, but KaloBios Pharmaceuticals went public and raised $70 million in late January, the first IPO for a US antibody company in more than a decade.